Table 1.
Baseline characteristics of population divided by MACCE-related situation.
| Characteristics | Overall (n=596) |
MACCE (n=281) |
No-MACCE (n=315) |
P value |
|---|---|---|---|---|
| Age (years) | 71.71 ± 9.36 | 72.46 ± 9.76 | 71.05 ± 8.96 | 0.068 |
| Male (n, %) | 212(35.6%) | 102(36.3%) | 110(34.9%) | 0.726 |
| BMI (kg/m2) | 24.53 ± 3.64 | 24.87 ± 3.93 | 24.22 ± 3.33 | 0.031 |
| Smoking (n, %) | 147(24.66%) | 77(27.40%) | 70(22.22%) | 0.143 |
| SBP (mmHg) | 133.56 ± 19.16 | 133.76 ± 19.02 | 133.37 ± 19.31 | 0.804 |
| DBP (mmHg) | 75.62 ± 11.21 | 75.03 ± 10.78 | 76.14 ± 11.58 | 0.229 |
| Laboratory variables | ||||
| TC (mmol/L) | 3.86(3.26~4.57) | 4.05(3.34~4.86) | 3.74(3.17~4.34) | <0.01 |
| TG(mmol/L) | 1.31(0.96~1.92) | 1.63(1.20~2.16) | 1.10(0.86~1.55) | <0.01 |
| HDL-C(mmol/L) | 1.22(1.00~1.47) | 1.20(0.98~1.45) | 1.23(1.02~1.49) | 0.127 |
| LDL-C(mmol/L) | 2.26(1.72~2.87) | 2.37(1.85~3.00) | 2.20(1.66~2.73) | <0.01 |
| FBG(mmol/L) | 5.82(5.05~7.63) | 6.59(5.34~8.81) | 5.38(4.90~6.40) | <0.01 |
| HbA1c(%) | 5.80(5.40~6.80) | 6.00(5.40~7.25) | 5.60(5.30~6.40) | <0.01 |
| TyG index | 8.80(8.36~9.26) | 9.10(8.80~9.47) | 8.48(8.19~8.86) | <0.01 |
| Case history | ||||
| Hypertension (n, %) | 467(78.36%) | 223(79.36%) | 244(77.46%) | 0.574 |
| T2DM (n, %) | 292(49.00%) | 163(58.00%) | 129(40.95%) | <0.01 |
| Dyslipidemia (n, %) | 388(65.10%) | 184(65.48%) | 204(64.76%) | 0.854 |
| Prior CVDs (n, %) | 506(84.90%) | 241(85.77%) | 265(84.13%) | 0.577 |
| Prior PCI (n, %) | 161(27.01%) | 79(28.11%) | 82(26.03%) | 0.568 |
| Prior stroke (n, %) | 264(44.30%) | 144(51.25%) | 120(38.10%) | <0.01 |
| Family history of CVDs (n, %) | 183(30.70%) | 78(27.76%) | 105(33.33%) | 0.141 |
| Medications | ||||
| Antiplatelet medication (n, %) | 565(94.80%) | 262(93.24%) | 303(96.19%) | 0.105 |
| ACEI/ARB (n, %) | 262(43.96%) | 155(55.16%) | 107(33.97%) | <0.01 |
| CCB (n, %) | 334(56.04%) | 155(55.16%) | 179(56.83%) | 0.683 |
| β-Blocker (n, %) | 351(58.89%) | 173(61.57%) | 178(56.51%) | 0.210 |
| Antidiabetic agents (n, %) | 253(42.45%) | 151(53.74%) | 102(32.38%) | <0.01 |
| Statins (n, %) | 516(86.58%) | 263(93.59%) | 253(80.32%) | <0.01 |
| Antidepressants (n, %) | 405(67.95%) | 189(67.26%) | 216(68.57%) | 0.732 |
| Benzodiazepines (n, %) | 214(35.91%) | 102(36.30%) | 112(35.56%) | 0.850 |
MACCE, major adverse cardiovascular and cerebrovascular events; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; TyG, triglyceride-glucose;T2DM, diabetes mellitus type 2; CVD, cardiovascular disease; PCI, percutaneous coronary intervention; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.